{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:27:59Z","timestamp":1773271679867,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncpendmet0500","type":"journal-article","created":{"date-parts":[[2007,4,23]],"date-time":"2007-04-23T14:14:01Z","timestamp":1177337641000},"page":"430-436","source":"Crossref","is-referenced-by-count":19,"title":["A treatment strategy for Graves' orbitopathy"],"prefix":"10.1038","volume":"3","author":[{"given":"Claudio","family":"Marcocci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Pinchera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpendmet0500_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/thy.1992.2.235","volume":"2","author":"A Pinchera","year":"1992","unstructured":"Pinchera A  et al. (1992) Classification of eye changes of Graves' disease. Thyroid 2: 235\u2013236","journal-title":"Thyroid"},{"key":"BFncpendmet0500_CR2","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C  et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562\u20133567","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0500_CR3","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0140-6736(03)12935-2","volume":"361","author":"P Vitti","year":"2003","unstructured":"Vitti P  et al. (2003) Europe is iodine deficient [letter]. Lancet 361: 1226","journal-title":"Lancet"},{"key":"BFncpendmet0500_CR4","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK  et al. (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0500_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/BF03345279","volume":"7","author":"L Bartalena","year":"2004","unstructured":"Bartalena L  et al. (2004) Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 27: 288\u2013294","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0500_CR6","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L  et al. (2000) Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21: 168\u2013199","journal-title":"Endocr Rev"},{"key":"BFncpendmet0500_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/105072504774193276","volume":"5","author":"M Marin\u00f2","year":"2004","unstructured":"Marin\u00f2 M  et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 5: 403\u2013406","journal-title":"Thyroid"},{"key":"BFncpendmet0500_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1572-0241.2002.05644.x","volume":"97","author":"SP Dourakis","year":"2002","unstructured":"Dourakis SP  et al. (2002) Acute severe steatohepatitis related to prednisone therapy. Am J Gastroenterol 97: 1074\u20131075","journal-title":"Am J Gastroenterol"},{"key":"BFncpendmet0500_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/BF03345386","volume":"28","author":"M Marin\u00f2","year":"2005","unstructured":"Marin\u00f2 M  et al. (2005) Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 28: 280\u2013284","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0500_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IMM Wakelkamp","year":"2005","unstructured":"Wakelkamp IMM  et al. (2005) Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 63: 323\u2013328","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFncpendmet0500_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje.1.02230","volume":"155","author":"WM Wiersinga","year":"2006","unstructured":"Wiersinga WM  et al. (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387\u2013389","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0500_CR12","unstructured":"European Group on Graves' orbitopathy [\n                    www.eugogo.org\n                    \n                  ] (Accessed 9 March 2007)"},{"key":"BFncpendmet0500_CR13","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ  et al. (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0500_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/BF03345277","volume":"27","author":"C Marcocci","year":"2004","unstructured":"Marcocci C  et al. (2004) Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest 27: 272\u2013280","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0500_CR15","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2003-030260","volume":"88","author":"C Marcocci","year":"2003","unstructured":"Marcocci C  et al. (2003) Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 88: 3561\u20133566","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0500","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:53:00Z","timestamp":1684439580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncpendmet0500"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0500","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}